General Guidance Template Felleskatalog text and Factual text



Similar documents
Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

Selected Requirements of Prescribing Information

Nursing 113. Pharmacology Principles

Nevirapine 200 mg tablets WHOPAR part 5 09/2010, version 1.0 (Matrix Laboratories Ltd), HA396 LABELLING. Page 1 of 8

QRD recommendations on pack design and labelling for centrally authorised non-prescription human medicinal products

Guidance for Industry

SR 5. W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1

PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)

General Principles for the Safety Assessment of Excipients

1. NAME OF THE MEDICINAL PRODUCT. Impavido 10 mg capsules Impavido 50 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. 1 capsule contains:

Course Curriculum for Master Degree in Clinical Pharmacy

Pharmacy Technician Syllabus 14152

Public Assessment Report Scientific discussion. Tenofovir disoproxil Teva (tenofovir disoproxil) SE/H/1432/01/DC

Narcotic drugs used for pain treatment Version 4.3

Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665

NEUROTONE THR 00904/0005 UKPAR

Maintenance of abstinence in alcohol dependence

PARACETAMOL REXIDOL. 600 mg Tablet. Analgesic-Antipyretic. Paracetamol 600 mg

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet

4 Clinical Particulars

What is homeopathy? HOMEOPATHIC. learn more about:

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

Analytical Specifications RIVAROXABAN

Working together for healthier living

National Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS

White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other.

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)

Nurse Initiated Medications Procedure

A Peak at PK An Introduction to Pharmacokinetics

See 17 for PATIENT COUNSELING INFORMATION. Revised: 3/2016 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR

DO YOU HAVE ITCHY ALLERGY EYES? Find out about lasting relief

FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN

Decentralised Procedure. Public Assessment Report

ENZAR FORTE TABLETS. (derived from Pancreatin USP) Sodium tauroglycocholate BPC 65mg (with sugar coating containing essential carminative oils)

SUMMARY OF PRODUCT CHARACTERISTICS. Buprenovet 0.3 mg/ml Solution for Injection for Dogs and Cats (AT, DE)

Patient information. How to Stop Smoking Before your Operation PIF 734 V5

Introduction to Enteris BioPharma

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

EMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - SEVERE AND SERIOUS HEPATIC REACTIONS -

Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006

Study (s) Degree Center Acad. Period Grado de Farmacia FACULTY OF PHARMACY 3 Annual PDG Farmacia-Nutrición Humana y Dietética

RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE

SUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product)

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Summary of Product Characteristics

Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o.

Bioequivalence Study Design Considerations. Dr. John Gordon

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., FRUCTUS

SUMMARY OF PRODUCT CHARACTERISTICS

PHARMACOLOGICAL PROPERTIES

Program Assistance Letter

LEFLUNOMIDE (Adults)

Dorset Cardiac Centre

Complete Pharmacy Technician Certificate Program 230 clock hours

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE)

MELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (WELL-ESTABLISHED MEDICINAL USE)

Introduction to pharmaceutical technology

THE PHARMACEUTICAL INDUSTRY

Low dose naltrexone as a treatment for multiple sclerosis

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

MANAGEMENT OF CHRONIC NON MALIGNANT PAIN

LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES. (paracetamol, caffeine and phenylephrine hydrochloride)

Dechra Veterinary Products Limited (A business unit of Dechra Pharmaceuticals PLC) Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK

Pain Control Aims. General principles of pain control. Basic pharmacokinetics. Case history demo. Opioids renal failure John Welsh 8/4/2010

M4E(R2): The CTD Efficacy

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin

Guidance for Industry

PUBLIC ASSESSMENT REPORT Scientific Discussion. Perindopril arginine Amlodipine FR/H/ /01-04/DC. Applicant: Servier

Public Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no:

Olanzapine Fda Indications

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis) caused by susceptible strains of organisms.

Guidance for Industry and Review Staff Target Product Profile A Strategic Development Process Tool

SUMMARY OF PRODUCT CHARACTERISTICS. Paracetamol mg for 1 ml of solution for infusion

NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997

Public Assessment Report Scientific discussion. Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no:

Summary of Product Characteristics

ZOVIRAX Cold Sore Cream

IT requirement specification Safety alert. Oral methotrexate 2.5mg and 10mg tablets

Learn More About Product Labeling

BEST PRACTICE GUIDANCE ON THE LABELLING AND PACKAGING OF MEDICINES

FOR ORAL OR RECTAL ADMINISTRATION FOR THE PREVENTION AND TREATMENT OF PORTAL-SYSTEMIC ENCEPHALOPATHY

MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines

Rivaroxaban (Xarelto ) by

DVT/PE Management with Rivaroxaban (Xarelto)

PATIENT INFORMATION LEAFLET. Forceval Junior Capsules

Guidance for Industry Safety Testing of Drug Metabolites

0.9% Sodium Chloride Injection, USP In VIAFLEX Plastic Container

MEDICATION GUIDE. TOPAMAX (TOE-PA-MAX) (topiramate) Tablets and Sprinkle Capsules

ehr Sharable Data - Prescribing Record Validation Rule Code Table Data requirement (Certified Level 1)

Comparison between New Oral Anticoagulants and Warfarin

GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8

Transcription:

Template Felleskatalog text Product name «Company name» Product name and company name (as shown on the outer package). Side 1 ATC-nr.: N05A A15 ATC code according to WHO index. T Reimbursement (we get this information directly from FEST 1 ). Medicines under additional monitoring (according to EMA). Warning against use by drivers of motor vehicles. We get this information directly from FEST 1. A, B, C, CF, F Prescription status. We get this information directly from FEST 1. Antipsykotikum. TABLETTER, filmdrasjerte 10 mg og 20 mg: Short description of therapeutic classification. Pharmaceutical form as given in the approved SPC. Declaration of ingredients List the ingredients in Norwegian (not Latin). For parenteral products, topical products and ophthalmic products you must list all excipients. For all other pharmaceutical forms: List only lactose, aspartame, phenylalanine, soy products (example soy lecithin), colouring agents and preservatives. Remember the colouring agent in capsules. You shall write the European code (E number) for preservatives and colouring agents in brackets. Furthermore, state a) use of sugar as sweetening agent in tablets and lozenges for chewing or sucking, and oral mixtures, («contains sugar» is sufficient) and b) flavour of mixtures. Indikasjoner: Reseptfri bruk: Give the range of indications, as approved in the SPC. Highlight nonprescription use under the subsection Reseptfri bruk.

Dosering: Indikasjon: Voksne: Barn: Spesielle pasientgrupper: Nedsatt lever- og nyrefunksjon: Nedsatt leverfunksjon: Nedsatt nyrefunksjon: Barn og ungdom: Eldre: Annet: Tilberedning/Håndtering: Administrering: Kontraindikasjoner: Normal dosage and duration of treatment. Dosage in renal impairment. Dosage for children and the elderly. Method for dosage titration, if relevant. If dose schedules vary considerably from one patient to another, this is to be stated. Administration: If you must swallow the tablet/capsule whole or if you can chew the tablet/capsule. State reason for this, for example, an unpleasant taste. Administration in relation to meals. Only absolute contraindications, according to the approved SPC Side 2 Forsiktighetsregler: Hjerte: Lunger: Hjelpestoffer: Bilkjøring og betjening av maskiner: Precautions. Don t include descriptions of clinical studies, only include the conclusions. Include only information of side effects if relevant as a precaution. Include warning against use by drivers of motor vehicles at the end of the section. Interaksjoner: Graviditet, amming og fertilitet: Graviditet: Amming: Fertilitet: Bivirkninger: Svært vanlige ( 1/10): Include particularly important interactions. On our website, we show information from FEST 1 about interactions at the end of this section. Use the division in left column when suited. Fertility: Capacity for reproduction. Give information about prevention of pregnancy under the subsection Graviditet. Use the classification in the left column.

Vanlige ( 1/100 til <1/10): Mindre vanlige ( 1/1000 til <1/100): Sjeldne ( 1/10 000 til <1/1000): Svært sjeldne (<1/10000), ukjent: If it s not possible to state frequency, you should use the organ classification. If possible, avoid expressions like «is reported», «in some cases», «are not seen» etc. Don t use tables in this section. Side 3 Blod/lymfe Endokrine: Gastrointestinale: Hjerte/kar: Hud: Immunsystemet: Infeksiøse: Kjønnsorganer/bryst: Lever/galle: Luftveier: Medfødte og genetiske sykdommer: Muskel-skjelettsystemet: Nevrologiske: Nyre/urinveier: Psykiske: Stoffskifte/ernæring: Svangerskap: Svulster/cyster: Undersøkelser: Øre: Øye: Øvrige: Overdosering/ Forgiftning: Symptomer:.... Behandling:.... Toxicological information. Estimated dose that gives symptoms of poisoning in adults and children. Use of specific antidote. Whenever possible our editorial staff will add a referral to the section «Poisoning».

Egenskaper: Klassifisering: Virkningsmekanisme: Absorpsjon: Proteinbinding: Fordeling: Halveringstid: Terapeutisk serumkonsentrasjon: Metabolisme: Utskillelse: Include only information of practical interest. Don t include descriptions of clinical trials. Classification: Give a short description of therapeutic use. Mode of action: How drugs act, general principles. Absorption: Rate of absorption, bioavailability (first pass metabolism). Protein binding: Binding to plasma proteins. Distribution: Volume of distribution (litre). Half-life: Half-life, durability, steady state and clearance (ml/minute). Side 4 Therapeutic serum concentration: Include this only when the effect of the drug is dependent of serum concentration. Metabolism: Include only information about pharmacologically active drug metabolites. Elimination: Renal and biliary excretion. Oppbevaring og holdbarhet: Andre opplysninger: Utlevering: Reseptfrie pakninger: Pakninger, priser og Normally you should not include information about storage and durability instructions, with the exception of special precautions once a product has been opened/made ready for use. For example interference with laboratory tests. Information about special restrictions regarding distribution, given by the Government. Information about nonprescription packages. Packages, reimbursement, and prices. We get information about reimbursement and prices directly from FEST 1.

refusjon: Byttegruppe: Byttegruppe: We show information about Byttegruppe only on the website. 1FEST: Data form the Norwegian Medicines Agency. Updated 1 th and 15 th every month. Side 5 Template Factual text Factual text is possible to use for those products where it is possible to refer to a complete Felleskatalog text. The complete Felleskatalog text must give information about the same substance and with same pharmaceutical formulation and strength. Product name «Company name» ATC-nr.: N05A A15 Product name and company name (as shown on the outer package). ATC code according to WHO index. T Reimbursement (we get this information directly from FEST 1 ). Medicines under additional monitoring (according to EMA). Warning against use by drivers of motor vehicles. We get this information directly from FEST 1. A, B, C, CF, F Prescription status. We get this information directly from FEST 1. Antipsykotikum. TABLETTER, filmdrasjerte 10 mg og 20 mg: Short description of therapeutic classification. Pharmaceutical form as given in the approved SPC. Declaration of ingredients List the ingredients in Norwegian (not Latin). For parenteral products, topical products and ophthalmic products you must list all excipients. For all other pharmaceutical forms: List only lactose, aspartame, phenylalanine, soy products (example soy lecithin), colouring agents and preservatives. Remember the colouring agent in capsules. You shall write the European code (E

number) for preservatives and colouring agents in brackets. Furthermore, state a) use of sugar as sweetening agent in tablets and lozenges for chewing or sucking, and oral mixtures, («contains sugar» is sufficient) and b) flavour of mixtures. Side 6 Indikasjoner: Reseptfri bruk: Dosering: Administrering: Give the range of indications, as approved in the SPC. Highlight nonprescription use under the subsection Reseptfri bruk. For tablets and capsules only: Administration: If you must swallow the tablet/capsule whole or if you can chew the tablet/capsule. State reason for this, for example, an unpleasant taste. Administration in relation to meals. Utlevering: Reseptfrie pakninger: Pakninger, priser og refusjon: Byttegruppe: Preparatreferanse: Information about special restrictions regarding distribution, given by the Government. Information about nonprescription packages. Packages, reimbursement, and prices. We get information about reimbursement and prices directly from FEST 1. Byttegruppe: We show information about Byttegruppe only on the website. Referral to product with complete Felleskatalog text. 1FEST: Data form the Norwegian Medicines Agency. Updated 1 th and 15 th every month. Tables in general: You can use tables in all sections, except for the section Side effects (Bivirkninger). Write footnote as number, and without brackets. Don t use bold italic in tables.